Min-Ying Huang

Abstract Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ /HER2-) breast cancer is the most common subtype in females, frequently challenged by resistance to endocrine therapy and CDK4/6 inhibitors. Here we show that N-acetylneuraminate synthase (NANS) is significantly upregulated in female HR+ /HER2- breast cancer patients, inversely correlating with patient prognosis.

1 Introduction Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer, which lacks the expression of estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2) and accounts for about 15% of all breast cancer cases.[1] Clinically, TNBC exhibits aggressively clinicopathological features with a high incidence of early recurrence and distant metastases and the worst outcomes.[1] Due to the absence of validated therapeutic targets, chemotherapy is...

1 Introduction Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer that lacks the expression of estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2), and exhibits the most aggressive clinicopathological features with early distant metastasis, relapse, and the worst outcomes.[1, 2] Cytotoxic chemotherapy is the mainstay of systemic treatment for this disease owing to its insensitivity to classical endocrine and HER2-targeted...